Drug intelligence / Profile preview

4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]benzenesulfonamide

Development stage: Unknown
Modality: Small Molecules

Overview

A synthetic small molecule belonging to the benzenesulfonamide class. It contains an imidazopyridine and pyrimidine moiety linked to a benzenesulfonamide group. This compound is experimental and not approved for clinical use. It has been studied as a potential inhibitor of cyclin-dependent kinase 2 (CDK2), which plays a key role in cell cycle regulation. No approved indications or marketed products are associated with this molecule as of June 2025[5][6][8].

Other names: 4-{[4-(imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}benzenesulfonamideBenzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2 yl)amino]CHEBI:43051DB02197DB-02197DB 02197

Targets

CDK2 (Cyclin-dependent kinase 2)

Beyond the preview

Go deeper on 4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]benzenesulfonamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]benzenesulfonamide.

Explore the full profile